Perspectives in Cholesterol-Lowering Therapy
نویسندگان
چکیده
منابع مشابه
Perspectives in Pharmacology New Molecular Targets for Cholesterol-Lowering Therapy
The use of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) in randomized clinical trials has established that cholesterol-lowering treatment reduces the risk of both cardiovascular and total mortality. This reduction in risk occurs in patients with or without existing cardiovascular disease and in patients with high or average plasma cholesterol concentrations. Ag...
متن کاملCHOLESTEROL LOWERING EFFECT OF RHEUM RIBS IN HYPERCHOLESTEROLEMIC RABBITS
The effects of ethanolic and aqueous extracts of Rheum ribs L. (RR) of the family polygonaceae was studied on serum cholesterol concentration in rabbits. To induce hypercholesterolemia, 0.5 g/kg/day of pure cholesterol powder was given orally to each rabbit for two weeks then cholesterol was halved and each group of animals was treated with a different regimen for another two weeks. Both t...
متن کاملCholesterol-lowering therapy evokes time-limited changes in serotonergic transmission.
A number of studies have reported an increased risk for violent deaths and depression in subjects with reduced serum cholesterol concentrations. Links with hypothesized impairment of serotonin neurotransmission have not been satisfactorily tested. In this investigation, the serum and membrane cholesterol, microviscosity of erythrocyte membranes, platelet serotonin uptake, and clinical parameter...
متن کاملStatin therapy: beyond cholesterol lowering and antiinflammatory effects.
Aggressive cholesterol lowering has gradually been adopted by clinicians as part of a standard treatment regimen for patients with documented coronary artery disease, including those who have had recent bypass surgery and acute coronary syndrome.1–3 According to the recently published National Cholesterol Education Program Adult Treatment Panel III (NCEP III) guidelines, those patients who have...
متن کاملLong-term hemostatic effects of cholesterol-lowering therapy with atorvastatin.
This study assessed hemostatic effects of an HMC-CoA reductase inhibitor, atorvastatin, on different parameters in 32 hypercholesterolemic patients of both sexes. In the patients and in 25 control subjects, plasma levels of tissue-type plasminogen activator, plasminogen activator inhibitor (PAI-1), D-dimer, prothrombin fragment 1 + 2 (F1 + 2), total cholesterol, triglycerides and fibrinogen had...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Circulation
سال: 2003
ISSN: 0009-7322,1524-4539
DOI: 10.1161/01.cir.0000072345.98581.24